AI Terminal
ADDvise Group B
Regulatory Filings • Dec 6, 2024
8222_iss_2024-12-06_52182227-e025-4070-bf9e-5e472b622ad9.pdf
Regulatory Filings
Open in ViewerOpens in native device viewer
ADDvise receives allocation decision worth approximately SEK 72 million
ADDvise Group's subsidiary Hettich Labinstrument AB has received an allocation decision from Region Stockholm worth approximately SEK 72 million. The allocation decision involves the delivery of blood specimen collection equipment over a four-year period, commencing in May 2025.
The allocation decision can be appealed up until December 20, 2024.
For further information, please contact:
Staffan Torstensson, CEO +46 704 33 20 19 [email protected]
Important information
This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 6, 2024 at 14:20 CET.
About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.5 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, [email protected], is the company's Certified Adviser. More information is available at www.addvisegroup.com.